Physician profile
Allison Hemingway
NPI 1063571354
$14,017.60
in general payments reported to CMS, 2019-2025
44 companies · $2,212 in 2025
The $2,212 reported for 2025 was more than what 94% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,113 · 2022: $3,196 · 2023: $3,173 · 2024: $3,324 · 2025: $2,212.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,708.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,708.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,721.63 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $2,028.35 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $1,581.06 | 2021-2025 | |
| Glaxosmithkline, LLC. | $1,500.67 | 2021-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Lilly USA, LLC | $778.84 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $751.41 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $568.47 | 2022-2025 | |
| Esperion Therapeutics, INC. | $536.35 | 2021-2025 | Nexletol, Nexlizet |
| Janssen Pharmaceuticals, INC | $499.72 | 2023-2025 | Spravato |
| Boehringer Ingelheim Pharmaceuticals, INC. | $415.94 | 2021-2025 | Jardiance |
| Amgen INC. | $245.40 | 2023-2025 | Evenity, Repatha, Otezla |
| Astellas Pharma US INC | $220.72 | 2023-2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $204.71 | 2023 | |
| Novartis Pharmaceuticals Corporation | $164.10 | 2022-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $150.81 | 2021-2024 | Trintellix |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $150.29 | 2025 | Terlivaz |
| Merck Sharp & Dohme LLC | $142.85 | 2021-2025 | Capvaxive, Gardasil 9 |
| Abbott Laboratories | $142.67 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Silk Road Medical, INC. | $134.31 | 2023 | Enroute Transcarotid Stent, Enroute Transcarotid Neuroprotection System |
| Ironwood Pharmaceuticals, INC | $122.61 | 2022-2023 | Linzess |
| Amarin Pharma, INC. | $118.39 | 2021-2022 | |
| Exact Sciences Corporation | $106.07 | 2023-2025 | Cologuard Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $92.20 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $72.89 | 2023-2024 | Rexulti, Abilify Maintena |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $68.40 | 2024-2025 | Xifaxan |
| Edwards Lifesciences Corporation | $53.58 | 2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Corcept Therapeutics | $41.49 | 2024 | Korlym |
| Daiichi Sankyo INC. | $39.15 | 2021 | |
| Baxter Healthcare | $35.11 | 2024 | Hillrom - Eli280 Cardiograph |
| Inspire Medical Systems, INC. | $35.10 | 2024 | Inspire |
| Alnylam Pharmaceuticals INC. | $28.86 | 2022 | |
| Boston Scientific Corporation | $27.59 | 2024 | |
| Shield Therapeutics INC | $27.58 | 2023-2025 | Accrufer |
| Lundbeck LLC | $27.07 | 2024 | Vyepti |
| Nestle Healthcare Nutrition INC. | $23.33 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $22.10 | 2024 | Opsumit, Uptravi |
| Sumitomo Pharma America, INC. | $21.93 | 2024 | Gemtesa |
| Teleflex LLC | $20.20 | 2024 | Urolift |
| Eisai INC. | $20.16 | 2024 | |
| Dexcom, INC. | $17.07 | 2024 | Dexcom G6 Transmitter |
| Allergan, INC. | $16.43 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $15.64 | 2022 | |
| Ibsa Pharma INC. | $13.43 | 2022 | |
| Genentech USA, INC. | $12.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allison Hemingway listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.